An Open-Label Safety and Tolerability Study of INCB062079 in Subjects With Advanced Hepatocellular Carcinoma and Other Malignancies

Conditions:   Advanced Hepatocellular Carcinoma (HCC);   Cholangiocarcinoma;   Esophageal Cancer;   Nasopharyngeal Cancer;   Serous Ovarian Cancer;   Solid Tumor Malignancies With Documented FGF19/FGFR4 Alteration
Intervention:   Drug: INCB062079
Sponsor:   Incyte Corporation
Not yet recruiting - verified May 2017

http://ift.tt/2qOdCE0